EP2846685A1 - Ventricular activation (rr) entropy change as a predictor of sudden cardiac death in cardiac resynchronization therapy patients - Google Patents
Ventricular activation (rr) entropy change as a predictor of sudden cardiac death in cardiac resynchronization therapy patientsInfo
- Publication number
- EP2846685A1 EP2846685A1 EP20130788256 EP13788256A EP2846685A1 EP 2846685 A1 EP2846685 A1 EP 2846685A1 EP 20130788256 EP20130788256 EP 20130788256 EP 13788256 A EP13788256 A EP 13788256A EP 2846685 A1 EP2846685 A1 EP 2846685A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- entropy
- cardiac rhythm
- interval
- measurement
- segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000008859 change Effects 0.000 title claims description 22
- 230000004913 activation Effects 0.000 title abstract description 6
- 230000002861 ventricular Effects 0.000 title abstract description 6
- 206010049418 Sudden Cardiac Death Diseases 0.000 title description 15
- 238000009125 cardiac resynchronization therapy Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 44
- 230000000747 cardiac effect Effects 0.000 claims abstract description 37
- 230000033764 rhythmic process Effects 0.000 claims description 34
- 238000005259 measurement Methods 0.000 claims description 25
- 238000004590 computer program Methods 0.000 claims description 15
- 238000004364 calculation method Methods 0.000 claims description 9
- 238000004422 calculation algorithm Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000012417 linear regression Methods 0.000 claims description 3
- 230000035790 physiological processes and functions Effects 0.000 claims description 2
- 230000000630 rising effect Effects 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 15
- 230000002123 temporal effect Effects 0.000 abstract description 9
- 238000004458 analytical method Methods 0.000 description 18
- 238000004891 communication Methods 0.000 description 15
- 230000035939 shock Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000002565 electrocardiography Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000005312 nonlinear dynamic Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 206010015856 Extrasystoles Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010058155 Heart alternation Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005291 chaos (dynamical) Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009022 nonlinear effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 230000005654 stationary process Effects 0.000 description 1
- 238000005309 stochastic process Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/352—Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/364—Detecting abnormal ECG interval, e.g. extrasystoles, ectopic heartbeats
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Definitions
- RR Ventricular Activation
- the present invention relates generally to cardiology. More particularly, the present invention relates to the dynamic analysis of cardiac rhythm to predict morbidity and mortality.
- Electrocardiograms have long been studied in order to analyze cardiac function and predict health, disease and mortality.
- linear methods in the time and frequency domains are used to analyze the information from the electrocardiogram.
- One such linear method is referred to as heart rate variability (HRV).
- HRV heart rate variability
- time domain analysis a range of normal values for HRV analyzed in the time domain, frequency domain and geometrically are established based on 24-hour ambulatory recordings. Similar metrics, particularly in the time domain, are not universally accepted for short- term recording so stratification of continuous data can be used.
- the irregularity in the time-sampled intervals of electrocardiographic ventricular activation can be accounted for in frequency domain analyses in order to calculate an estimate of the power spectrum density (PSD).
- PSD power spectrum density
- PSD estimations are performed as a method of cardiac assessment using the FFT (Welch's periodogram) and the parametric maximum-entropy "forward-backward linear least squares" autoregressive (AR) methods.
- FFT Frequency-to-frequency transform
- AR autoregressive
- spectrum powers are calculated by integrating the spectrum over the frequency bands.
- the parametric AR method models the time series as a linear combination of complex harmonic functions, which include pure sinusoids and real exponentials as special cases, and fits a function of frequency with a predefined number of poles (frequencies of infinite density) to the spectrum.
- the AR method asserts that the position and shape of a spectral peak is determined by the corresponding complex frequency and that the height of the spectral peak contains little information about the complex amplitude of the complex harmonic functions.
- the spectrum is divided into components and the band powers are obtained as powers of these components.
- Nonlinear dynamic analyses are an alternate approach for understanding the complexity of biological systems.
- a nonlinear system has an output that is simply "not linear,” i.e., any information that fails criteria for linearity, i.e., output is proportional to input (e.g., Ohm's law), and superposition (behavior predicted by dissecting out individual input/output relationships of sub-components).
- FIG. 1A illustrates fractal temporal processes of a healthy RR.
- FIG. 1 B illustrates wavelet analysis of healthy RR time series of >1500 beats (x-axis is time, y-axis is wavelet scale (5 to 300 sees).
- FIG. 1 C illustrates the wavelet amplitudes.
- FIGS. 2A-2E It is quite common for the output of nonlinearly coupled control systems to generate behaviors that defy explanation based on conventional linear models, as illustrated in FIGS. 2A-2E.
- Characteristic behaviors of nonlinear systems include self- sustained, periodic waves (e.g., ventricular tachycardia), abrupt changes in output (e.g., sudden onset of ventricular fibrillation) and, possibly, chaos.
- FIGS. 2A-2E illustrate an RR time series demonstrating quantifiable nonlinear dynamics that are distinct within patients with OSA, as illustrated in FIGS. 2A-2C, and also distinct within healthy individuals at high altitude, as illustrated in FIGS. 2D-2E.
- nonlinear systems that appear to be very different in their specific details may exhibit certain common output patterns, a characteristic referred to as universality.
- outputs may change in a sudden, discontinuous fashion (e.g., bifurcation), often resulting from a very small change in one of the control modules.
- the same system may produce a wildly irregular output that becomes highly periodic or vice versa (e.g., electrical alternans, ST-T wave alternans preceding ventricular fibrillation, pulsus alternans during congestive heart failure)
- the Poincare plot is a graphical representation of the correlation between successive RR intervals, i.e. plot of RRn+1 as a function of RRn.
- the significance of this plot is that it is the two-dimensional reconstructed phase space (i.e., the projection of the system attractor that describes the dynamics of the time series).
- DFA Detrended fluctuation analysis
- CM short-term
- ⁇ 3 ⁇ 4, range 16 ⁇ n ⁇ 64 long- term fluctuation
- 0 ⁇ a ⁇ 0.5 indicates a large value is followed by a small value and vice versa
- 0.5 ⁇ a ⁇ 1 .0 indicates a large value is likely to be followed by a large value.
- An a value of 0.5, 1 .0, >1 .0, or >1 .5 indicates white noise, 1/f noise, different kinds of noise, or brown noise (integral of white noise), respectively.
- thermodynamic entropy the information entropy can be calculated for any probability distribution (i.e., occurrence of an event that had a probability of occurring out of the space of possible events).
- the infornnation entropy quantifies the amount of information needed to define the detailed microscopic state of a system, given its macroscopic description, and can be converted into its thermodynamic counterpart based on the Boltzmann distribution. Recent experimental evidence supports this method of conversion.
- ShanEn measures information as the decrease of uncertainty at a receiver (or physiological process).
- ShanEn of the line length distribution is defined as where is the number of length / lines such that
- the reduced AG would be equal to the minimum number of yes/no questions (using log 2 ) that needed to be answered in order to fully specify the microscopic state, given the macroscopic state.
- An increase in Shannon entropy indicates loss of information.
- ApEn approximate entropy
- SampEn is the conditional probability that that two short templates of length m that match within an arbitrary tolerance r will continue to match at the next point m + 1 .
- SampEn is calculated by first forming a set of vectors u s of length m where m represents the embedding dimension and N is the number of measured RR intervals. The distance between these vectors is defined as the maximum absolute difference between the corresponding elements
- COSEn an optimized form of the SampEn measure, was originally designed and developed at the University of Virginia for the specific purpose of discriminating atrial fibrillation (AF) from normal sinus rhythm (NSR) at all heart rates using very short time series of RR intervals from surface ECGs (i.e., as few as 12 heart beats).
- AF atrial fibrillation
- NSR normal sinus rhythm
- COSEn smaller values indicate a greater likelihood that similar patterns of RR fluctuation will be followed by additional similar measurements. If the time series is highly irregular, the occurrence of similar patterns will not be predictive for the following RR fluctuations and the COSEn value will be relatively large.
- a method of nonlinearly determining health and mortality includes obtaining a ventricular activation (RR) time series from a subject for multiple temporal intervals.
- the method also includes calculating a cardiac entropy in the RR time series over the temporal intervals using coefficient of sample entropy (COSEn).
- COSEn coefficient of sample entropy
- the method includes comparing the cardiac entropy between the intervals to determine health and mortality.
- the absolute and relative changes in entropy over a patient's follow up period provide dynamic information regarding health and mortality risk.
- the determination of health and mortality can then be used to create a treatment plan for the subject.
- the treatment plan created can include monitoring the subject's cardiac rhythms and other physiological signals, including but not limited to respiration, blood pressure, oxygen saturation, temperature and electroencephalogram.
- the subject can further be one selected from the group consisting of primates, dogs, guinea pigs, rabbits, horses, cats and other organisms.
- FIG. 1 A illustrates fractal temporal processes of a healthy RR according to an embodiment of the present invention.
- FIG. 1 B illustrates wavelet analysis of healthy RR time series of >1500 beats (x-axis is time, y-axis is wavelet scale (5 to 300 sees) according to an embodiment of the present invention.
- FIG. 1 C illustrates the wavelet amplitudes according to an embodiment of the present invention.
- FIGS. 2A-2E illustrate an RR time series demonstrating quantifiable nonlinear dynamics that are distinct within patients with OSA, as illustrated in FIGS. 2A-2C, and also distinct within healthy individuals at high altitude, as illustrated in FIGS. 2D-2E according to an embodiment of the present invention.
- Fig. 3 shows analysis of heart rate variability.
- Fig. 4 shows graphs of calculated change in entropy over time for patients at risk of SCD, in accordance with an aspect of the invention.
- Fig. 5 is a diagram illustrating vital demographics of patients in an observational study in accordance with the invention.
- Fig. 6 shows Kaplan-Meier survival curves for the patients in Fig. 5.
- Fig. 7 shows Hazard Ratios for multiple parameters of SCD patients.
- Fig. 8 shows Hazard Ratios for multiple parameters of patient death in the study due to all causes.
- FIG. 9 is a block diagram of an illustrative computer system capable of implementing the methods of the present invention.
- a method allows for the nonlinear assessment of health and mortality.
- ventricular activation (RR) time series from a subject for a temporal interval are obtained.
- a first and second cardiac entropy in the RR time series over the temporal interval are determined.
- the first and second cardiac entropy are compared, to determine health and mortality. This information can then be used to determine a treatment plan for the subject, such as increased monitoring for pathophysiological states.
- a method for assessing the risk of sudden cardiac death (SCD) by comparing cardiac RR interval rate of entropy change over a predefined time interval for a patient receiving Cardiac Resynchronization Therapy (CRT) to determine changes in entropy of normal sinus rhythm (NSR) and determining increased risk of SCD when the NSR entropy of the patient has increased.
- CTR Cardiac Resynchronization Therapy
- the coefficient of entropy is a calculation of an entropy rate (or entropy) of an RR interval series after it has been unit mean normalized (dividing each observation by the mean of the series). This is analogous to the coefficient of variation, which is the standard deviation after normalization by the mean.
- the calculation of the coefficient of entropy is accomplished by subtracting the natural logarithm of the mean from the original entropy calculation.
- the coefficient of entropy calculated for Q in this way is especially effective and we give it the name coefficient of sample entropy or COSEn for short and denote it by Q * .
- the dynamics of cardiac rhythms can be quantified by entropy and entropy rate under the framework of continuous random variables and stochastic processes.
- the entropy of a continuous random variable X with density f is
- entropy rate is the entropy of the conditional distribution of the present observation given the past.
- the entropy rate for i.i.d. sequences reduces to the entropy of the common distribution.
- E_- ⁇ og(f(X x ,X 2 ,...,X ) can still be estimated empirically. These are the fundamental calculations in ApEn and SampEn.
- the patients (age 51 ⁇ 12 yrs, male 66%, white 82%, DM 26%, HTN 46%, ICM 32%, EF 20 ⁇ 8%, NYHA class 2.3 ⁇ 0.8) were well treated medically for heart failure.
- Entropy was measured using coefficient of sample entropy (COSEn), based on Kolmogorov-Sinai entropy with roots in chaos theory.
- entropy change was measured as the slope of linear regression fit to values at baseline and subsequent clinic visits excluding shock.
- ICD shocks or deaths from ventricular tachyarrhythmias were used as a specific surrogate for SCD.
- entropy change was measured as ⁇ / ⁇ , the change in entropy over two routine 6 month clinical visits preceding an ICD shock (and excluding the clinical visit after the ICD shock).
- the ⁇ / ⁇ for the time interval preceding an ICD shock was a strong predictor of increased risk of SCD (where ICD shock is used as a surrogate for SCD).
- Fig. 5 is a graph illustrating the
- Fig. 6 shows Kaplan-Meier curves for these patients, per quartile of ⁇ / ⁇ . As shown, patients in the 4 th quartile for ⁇ / ⁇ had the lowest survival probability.
- Fig. 7 shows hazard ratios for SCD for multiple parameters, and Fig. 8 shows hazard ratios for all deaths for multiple parameters. As shown, ⁇ / ⁇ alone as a predictor had a confidence interval (CI) of 95%.
- CI confidence interval
- FIG. 9 is an illustrative block diagram for a computer system 100 for implementation of an exemplary embodiment or portion of an embodiment of present invention.
- a method or system of an embodiment of the present invention may be implemented using hardware, software or a
- the invention was implemented in software running on a general purpose computer 100 as illustrated in FIG. 1 .
- the computer system 100 may include one or more processors, such as processor 104.
- the Processor 104 is connected to a communication infrastructure 106 (e.g., a communications bus, cross-over bar, or network).
- the computer system 100 may include a display interface 102 that forwards graphics, text, and other data from the communication infrastructure 106 (or from a frame buffer not shown) for display on the display unit 830.
- the computer system 10 may also include a main memory 108, preferably random access memory (RAM), and may include a secondary memory 1 10.
- the secondary memory 1 10 may include, for example, a hard disk drive 1 12 and/or a removable storage drive 1 14, representing a floppy disk drive, a magnetic tape drive, an optical disk drive, a flash memory, etc.
- the removable storage drive 1 14 reads from and/or writes to a removable storage unit 1 18 in a well-known manner.
- Removable storage unit 1 18, represents a floppy disk, magnetic tape, optical disk, etc. which is read by and written to by removable storage drive 1 14.
- removable storage unit 1 18 includes a computer usable storage medium having stored therein computer software and/or data.
- secondary memory 1 10 may include other means for allowing computer programs or other instructions to be loaded into computer system 100.
- Such means may include, for example, a removable storage unit 122 and an interface 120.
- removable storage units/interfaces include a program cartridge and cartridge interface (such as that found in video game devices), a removable memory chip (such as a ROM, PROM, EPROM or EEPROM) and
- removable storage units 122 and interfaces 120 which allow software and data to be transferred from the removable storage unit 122 to computer system 100.
- the computer system 100 may also include a communications interface 124.
- Communications interface 124 allows software and data to be transferred between computer system 100 and external devices.
- Examples of communications interface 824 may include a modem, a network interface (such as an Ethernet card), a
- communications interface 124 Software and data transferred via communications interface 124 are in the form of signals 828 which may be electronic, electromagnetic, optical or other signals capable of being received by communications interface 124.
- Signals 128 are provided to communications interface 124 via a communications path (i.e., channel) 126.
- Channel 126 (or any other communication means or channel disclosed herein) carries signals 128 and may be implemented using wire or cable, fiber optics, blue tooth, a phone line, a cellular phone link, an RF link, an infrared link, wireless link or connection and other communications channels.
- computer program medium and “computer usable medium” are used to generally refer to media or medium such as removable storage drive 1 14, a hard disk installed in hard disk drive 1 12, and signals 128.
- These computer program products are means for providing software to computer system 100.
- the computer program product may comprise a computer useable medium having computer program logic thereon.
- the invention includes such computer program products.
- the "computer program product” and “computer useable medium” may be any computer readable medium having computer logic thereon.
- Computer programs may be stored in main memory 108 and/or secondary memory 1 10. Computer programs may also be received via communications interface 124. Such computer programs, when executed, enable computer system 100 to perform the features of the present invention as discussed herein. In particular, the computer programs, when executed, enable processor 104 to perform the functions of the present invention.
- the software may be stored in a computer program product and loaded into computer system 100 using removable storage drive 1 14, hard drive 1 12 or communications interface 124.
- the control logic when executed by the processor 104, causes the processor 104 to perform the functions of the invention as described herein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Signal Processing (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645830P | 2012-05-11 | 2012-05-11 | |
| PCT/US2013/040677 WO2013170232A1 (en) | 2012-05-11 | 2013-05-11 | Ventricular activation (rr) entropy change as a predictor of sudden cardiac death in cardiac resynchronization therapy patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2846685A1 true EP2846685A1 (en) | 2015-03-18 |
| EP2846685A4 EP2846685A4 (en) | 2016-01-06 |
Family
ID=49551325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13788256.9A Withdrawn EP2846685A4 (en) | 2012-05-11 | 2013-05-11 | CHANGING VENTRICULAR ACTIVATION ENTROPY (RR) AS A FACTOR FOR PREDICTING HEART SUFFERING IN PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2846685A4 (en) |
| WO (1) | WO2013170232A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9960435B2 (en) | 2013-07-22 | 2018-05-01 | Nissan Motor Co., Ltd. | Fuel-cell-stack manufacturing method and fuel-cell-stack |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6804551B2 (en) * | 1998-03-17 | 2004-10-12 | University Of Virginia Patent Foundation | Method and apparatus for the early diagnosis of subacute, potentially catastrophic illness |
| WO1999047040A1 (en) * | 1998-03-17 | 1999-09-23 | The University Of Virginia Patent Foundation | Method and apparatus for the early diagnosis of subacute, potentially catastrophic illness |
| US7882167B2 (en) * | 2005-02-18 | 2011-02-01 | Beth Israel Deaconess Medical Center | Complexity-based dynamical analysis of a network |
| US8983584B2 (en) * | 2007-04-12 | 2015-03-17 | University Of Virginia Patent Foundation | Method, system and computer program product for non-invasive classification of cardiac rhythm |
| US8346349B2 (en) * | 2008-01-16 | 2013-01-01 | Massachusetts Institute Of Technology | Method and apparatus for predicting patient outcomes from a physiological segmentable patient signal |
| WO2009100133A1 (en) * | 2008-02-04 | 2009-08-13 | University Of Virginia Patent Foundation | System, method and computer program product for detection of changes in health status and risk of imminent illness |
| CA2747057A1 (en) * | 2008-12-16 | 2010-07-08 | Bodymedia, Inc. | Method and apparatus for determining heart rate variability using wavelet transformation |
| US8679009B2 (en) | 2010-06-15 | 2014-03-25 | Flint Hills Scientific, Llc | Systems approach to comorbidity assessment |
-
2013
- 2013-05-11 EP EP13788256.9A patent/EP2846685A4/en not_active Withdrawn
- 2013-05-11 WO PCT/US2013/040677 patent/WO2013170232A1/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9960435B2 (en) | 2013-07-22 | 2018-05-01 | Nissan Motor Co., Ltd. | Fuel-cell-stack manufacturing method and fuel-cell-stack |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013170232A1 (en) | 2013-11-14 |
| EP2846685A4 (en) | 2016-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pham et al. | Heart rate variability in psychology: A review of HRV indices and an analysis tutorial | |
| Mortensen et al. | Multi-class stress detection through heart rate variability: A deep neural network based study | |
| Ellis et al. | A careful look at ECG sampling frequency and R-peak interpolation on short-term measures of heart rate variability | |
| Costa et al. | Multiscale entropy analysis of biological signals | |
| Mandala et al. | ECG-based prediction algorithm for imminent malignant ventricular arrhythmias using decision tree | |
| Raheja et al. | An IoT enabled secured clinical health care framework for diagnosis of heart diseases | |
| US20210251552A1 (en) | System and method for risk stratification based on dynamic nonlinear analysis and comparison of cardiac repolarization with other physiological signals | |
| Panigrahy et al. | Extraction of fetal ECG signal by an improved method using extended Kalman smoother framework from single channel abdominal ECG signal | |
| Singh et al. | Ectopic beats in approximate entropy and sample entropy-based HRV assessment | |
| Maurer et al. | Explainable artificial intelligence on biosignals for clinical decision support | |
| CN117271977B (en) | HRV data preprocessing method, device and electronic equipment | |
| CN116504398A (en) | Method and system for cardiac arrhythmia prediction using a transformer-based neural network | |
| US12303279B2 (en) | Electrocardiogram data processing server, method and computer program for displaying analysis data of electrocardiogram signal | |
| Lee et al. | A real-time abnormal beat detection method using a template cluster for the ECG diagnosis of IoT devices | |
| Kuetche et al. | Signal quality indices evaluation for robust ECG signal quality assessment systems | |
| US9839364B2 (en) | Ventricular activation (RR) entropy change as a predictor of sudden cardiac death in cardiac resynchronization therapy patients | |
| Chen et al. | Probabilistic model-based approach for heart beat detection | |
| Georgieva-Tsaneva et al. | Cardio-diagnostic assisting computer system | |
| Georgieva-Tsaneva | Interactive Cardio System for Healthcare Improvement | |
| EP4434462A1 (en) | Method and system for determining cardiac abnormalities using chaos-based classification model from multi-lead ecg | |
| EP2846685A1 (en) | Ventricular activation (rr) entropy change as a predictor of sudden cardiac death in cardiac resynchronization therapy patients | |
| Su et al. | Reconsider photoplethysmogram signal quality assessment in the free living environment | |
| Rodriguez et al. | Embedded system based on an ARM microcontroller to analyze heart rate variability in real time using wavelets | |
| Fraser et al. | Time-delay lifts for physiological signal exploration: An application to ECG analysis | |
| Signorini et al. | Assessment of nonlinear dynamics in heart rate variability signal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20141119 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20151204 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 5/0456 20060101ALN20151130BHEP Ipc: A61B 5/024 20060101ALI20151130BHEP Ipc: G06F 19/00 20110101ALI20151130BHEP Ipc: A61B 5/00 20060101ALI20151130BHEP Ipc: A61B 5/0468 20060101ALN20151130BHEP Ipc: A61B 5/04 20060101AFI20151130BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20170123 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 5/0468 20060101ALN20181115BHEP Ipc: A61B 5/04 20060101AFI20181115BHEP Ipc: A61B 5/00 20060101ALI20181115BHEP Ipc: A61B 5/0456 20060101ALN20181115BHEP Ipc: G06F 19/00 20180101ALI20181115BHEP Ipc: A61B 5/024 20060101ALI20181115BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20181207 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 5/04 20060101AFI20181126BHEP Ipc: G06F 19/00 20180101ALI20181126BHEP Ipc: A61B 5/0456 20060101ALN20181126BHEP Ipc: A61B 5/00 20060101ALI20181126BHEP Ipc: A61B 5/0468 20060101ALN20181126BHEP Ipc: A61B 5/024 20060101ALI20181126BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20190418 |